Hepatitis B virus (HBV) infection is a global public health concern. HBV causes chronic infection in patients and can lead to liver cirrhosis, hepatocellular carcinoma, and other severe liver diseases. Thus, understanding HBV-related pathogenesis is of particular importance for prevention and clinical intervention. HBV surface antigens are indispensable for HBV virion formation and are useful viral markers for diagnosis and clinical assessment. During chronic HBV infection, HBV genomes may acquire and accumulate mutations and deletions, leading to the expression of defective HBV surface antigens. These defective HBV surface antigens have been found to play important roles in the progression of HBV-associated liver diseases. In this review, we focus our discussion on the nature of defective HBV surface antigen mutations and their contribution to the pathogenesis of fulminant hepatitis B. The relationship between defective surface antigens and occult HBV infection are also discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102499 | PMC |
http://dx.doi.org/10.3748/wjg.v24.i31.3488 | DOI Listing |
China CDC Wkly
December 2024
School of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
What Is Already Known About This Topic?: As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).
What Is Added By This Report?: The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.
Lancet Reg Health Eur
February 2025
Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.
Background: The health of the marginalized populations is crucial for public health and inequalities. The World Health Organization (WHO) Global Hepatitis Report 2024 stated that over 304 million people were living with Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) infection in 2022. We performed HBV/HCV screenings among marginalized communities to reveal hidden infections and link-to-care positive participants.
View Article and Find Full Text PDFZhonghua Gan Zang Bing Za Zhi
December 2024
Senior Department of Infection Disease, the Fifth Medical Center of PLA General Hospital, Beijing100039, China.
The article reviews the role and functional diversity of B cells in chronic hepatitis B (CHB). B cells play a crucial role in humoral immunity, participating in the clearance of hepatitis B virus (HBV) through antibody production, antigen presentation, and immune regulation. In HBV infection, B cells exhibit antigenic heterogeneity, with immune responses to different HBV antigens varying.
View Article and Find Full Text PDFBMC Infect Dis
December 2024
Department of Medical Laboratory Science, Faculty of Applied Health Sciences, Edo State University, Uzairue, Edo State, Nigeria.
Background: Hepatitis B virus (HBV) infection remains a major health challenge in Nigeria, with high prevalence rates among pregnant women. The prevalence of overt and occult hepatitis B infection (HBI and HBI) among pregnant women was investigated to understand the burden and associated risk factors in this population.
Methods: A cross-sectional study was conducted among 200 pregnant women.
J Chin Med Assoc
December 2024
Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Hepatitis B virus (HBV) infection is regarded as a major health concern worldwide. In patients with chronic HBV infection, exhausted virus-specific CD8+ T cells, resulting from the activation of the programmed cell death protein 1 and programmed death ligand 1 axis, play a key role in the chronicity of infection. Functional cure for HBV, defined as the seroclearance of hepatitis B surface antigen (HBsAg), is viewed as the optimal goal of chronic HBV infection treatment because HBsAg loss is associated with a low risk of hepatocellular carcinoma and a relatively favorable prognosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!